Spots Global Cancer Trial Database for Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
Official Title: Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study
Study ID: NCT02587884
Conditions
Interventions
Study Description
Brief Summary: The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Contact Details
Name: Shen Feng, MD
Affiliation: Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
